DEPARTMENT OF HEALTH
DRUG OFFICE
DRUG REGISTRATION AND IMPORT/EXPORT CONTROL DIVISION

Guidance Notes on
Registration of Pharmaceutical Products/Substances

Preface

This document aims to provide guidance on making application for registration of pharmaceutical products and should be read in conjunction with the current laws governing pharmaceutical products in Hong Kong, which include the following Ordinances and their relevant subsidiary legislation:

- Pharmacy and Poisons Ordinance (Chapter 138);
- Antibiotics Ordinance (Chapter 137);
- Dangerous Drugs Ordinance (Chapter 134);
- Undesirable Medical Advertisements Ordinance (Chapter 231);

If there is any contradiction between this document and any written law, the latter shall take precedence. Applicants are strongly encouraged to familiarise themselves with the contents of this guidance document before submitting their applications.

Pharmaceutical products subject to registration

1. Under the Pharmacy and Poisons Regulations, pharmaceutical products must be registered with the Pharmacy and Poisons Board before they can be sold, offered for sale, distributed or possessed for the purposes of sale, distribution or other use. “Pharmaceutical product” means any substance, or combination of substances

   (A) presented as having properties for treating or preventing disease in human beings or animals; or

   (B) that may be used in, or administered to, human beings or animals, either with a view to –

      (i) restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action; or
      (ii) making a medical diagnosis.

(Feb 2017)
2. In considering whether or not your product is a “pharmaceutical product”, you should take into account the composition of your product and the nature of the claims you make in relation to the product. In general, if your product contains a drug substance in its composition, or if it carries “medicinal” claims in its label, leaflet, brochure, wrapper, advertisements and other promotional materials, it will fall within the meaning of pharmaceutical product and registration is required. Products commonly referred to as cosmetics, toiletries and disinfectants which do not contain any drug ingredient in its composition and which are sold without any medicinal claims may be excluded. However, it is your obligation to have complete knowledge of the ingredients of products. If the composition of the products for sale is found to contain substances that fall within the meaning of pharmaceutical product, you might commit an offence of the sale of an unregistered pharmaceutical product.

Criteria for registration

3. Your pharmaceutical product will only be approved for registration if it meets the criteria of safety, efficacy and quality relevant to it.

Who should apply?

4. If your pharmaceutical product is manufactured in Hong Kong, the person responsible for obtaining registration of the product is the licensed manufacturer, or the licensed wholesale dealer contracting with the licensed manufacturer.

5. If your pharmaceutical product is manufactured outside Hong Kong, the person responsible for obtaining registration is the licensed wholesale dealer who imported the pharmaceutical product, or the Hong Kong branch, subsidiary, representative, agent or distributor of the overseas manufacturer.

Pharmaceutical products not subject to registration

6. Products which fall under the following categories are not required to be registered with the Pharmacy and Poisons Board:

   (A) products containing only proprietary Chinese medicines or Chinese herbal medicines as defined in the Chinese Medicine Ordinance (Cap. 549);
(B) drug substances imported by licensed manufacturers solely for the purpose of manufacturing their own pharmaceutical products;

(C) products possessed or used under the direction of a registered medical practitioner or a registered dentist for the treatment of a particular patient, or of a registered veterinary surgeon for the treatment of a particular animal;

(D) products imported for re-export only;

(E) products manufactured in Hong Kong for export by the licensed manufacturer only;

(F) products administered for the purposes of a clinical trial/medicinal test in accordance with a clinical trial/medicinal test certificate issued under the Pharmacy and Poisons Regulations.

**Where to apply?**

7. Manual submission of application for registration of pharmaceutical product is no longer accepted with effect from 1 Jan 2017. You should submit your new application via the online system Pharmaceutical Registration System 2.0 (PRS 2.0) at the website below:

https://www.drugoffice.gov.hk/prs2-ext/client_authentication.jsp

**How to apply?**

8. You should submit the new application via PRS 2.0 along with the followings:

   (A) the application fee, currently at $1,100 (Please also see paragraph 13) via PRS 2.0 with credit card/PPS online payment services, or alternatively in person by cash or cheque along with the notification of payment at the following address:

   Drug Registration and Import/Export Control Division  
   Drug Office, Department of Health  
   3/F, Public Health Laboratory Centre,  
   382 Nam Cheong Street,  
   Shek Kip Mei, Kowloon,  
   Hong Kong. (Enquiries: 2319 8458)

   (B) for products manufactured outside Hong Kong, an authorization

(Feb 2017)
letter from the overseas manufacturer for the applicant is required;

(C) the following particulars:

a) Soft copy of the business registration certificate of the applicant;

b) An authorized person for the application, contact telephone and facsimile numbers and content of the submission dossier. Please declare in the PRS 2.0 system that the applicant “agrees to submit additional or updated supporting documents when required”;

c) Soft copy and certified true copy (Please see sub-paragraph D below) of the manufacturer’s licence;

d) For products manufactured outside Hong Kong: Information on the manufacturing facilities and practices of the manufacturer; (For application relating to a pharmaceutical product manufactured outside Hong Kong, the methods, standards and conditions of manufacture of the pharmaceutical product will also be taken into consideration. Applicants should therefore supply detailed information regarding the manufacturer including the manufacturing and quality control facilities, technical personnel, etc)

e) Soft copy and certified true copy (Please see sub-paragraph D below) of Good Manufacturing Practices (GMP) certificate of the manufacturer (Note: With effect from 1 Jan 2016, all applications for registration of pharmaceutical products must include evidence of manufacturers’ compliance with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) GMP standards. For details, please refer to “Letter to the Pharmaceutical Trade” and “Questions and Answers on PIC/S GMP Requirements for Registration of Pharmaceutical Products” available at the following website: http://www.drugoffice.gov.hk);

f) Soft copy and original or certified true copy (Please see sub-paragraph D below) of free sale certificate of the product issued by the country of origin;

g) One set of prototype sales pack (e.g. outer carton, container label, and
other component(s) comprising the sales pack) for each pack size of the
product, complying with the labelling requirements (Please refer to the
“Guidelines on the Labelling of Pharmaceutical Products” at Appendix 2);

h) For products containing a new chemical or biological entity:

(i) official evidence of registration approval of the product (e.g.
soft copy and original or certified true copies (Please see sub-
paragraph D below) of free sale certificates) in two or more of
the following countries: Australia, Austria, Belgium, Bulgaria,
Canada, Cyprus, Czech Republic, Denmark, Estonia, Finland,
France, Germany, Greece, Holland, Hungary, Ireland, Italy,
Japan, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal,
Romania, Slovak Republic, Slovenia, Spain, Sweden,
Switzerland, UK and USA;

(ii) expert evaluation reports on the safety, efficacy and quality of
the product. Curriculum vitae of the expert and the expert’s
signature on the corresponding reports are required;

(iii) European Union Risk Management Plan (EU-RMP) and/or US
Food and Drug Administration (FDA) Risk Evaluation and
Mitigation Strategy (REMS) required for the product, if
applicable. Information on whether any of the risk management
plan activities and mitigation strategies will be implemented in
Hong Kong;

(iv) Proposed package insert of the product. Where the package
insert is in the form of a patient information leaflet, a
prescribing information leaflet for healthcare professionals for
use in Hong Kong should also be submitted;

i) Clinical and scientific documentation substantiating the safety and
efficacy of the product:

(i) Except for generic product applications received on or after 1
Oct 2012 and their originator products have been registered in
Hong Kong for over 8 years (please see paragraph j below);

(ii) For biosimilar product applications, please also refer to “Guidance Notes for Registration of Biosimilar Products” available at the following website:

j) The following document(s) to support the proposed indication(s), dosage, route of administration and other contents of the package insert (if any): (Cross-referencing to documents should be made by referring to the page number of the reference documents and the relevant parts of the reference documents shall be highlighted clearly)

(i) copy of reputable references (e.g. American Hospital Formulary Service Drug Information, British National Formulary (BNF), Medicines Compendium, Drug Information Handbook, Drug Facts and Comparisons, Martindale The Complete Drug Reference or Physicians’ Desk Reference); and

/ or

(ii) documentary evidence showing that the package insert has been approved by one of the listed countries in section 8 (C) h) (i);

k) (i) In the case of applications for registration of pharmaceutical substances:
Sample of the pharmaceutical substance as it will be sold to the purchaser. For imported substance, you are reminded to apply for an import licence before importing the samples. Please refer to the attached “How to apply for Import and Export Licences for Pharmaceutical Products and Medicines”, “How to complete Import and Export Licence forms for Pharmaceutical Products and Medicines” and “Import and Export Licences Notes for the Guidance of Applicants” at Appendix 4 for details.

OR

(ii) In the case of applications for registration of pharmaceutical
products:
- Scanned image in PDF format (scanning based on 300dpi or higher) or photograph image in JPEG format (pixel size not less than 320x200) of your prototype sales pack or sample sales pack, including the inner container/packaging and the unit dose form image of the product sample, clearly showing the complete content of the prototype sales pack and its component(s), for examples:
  - colour and engraving/printing of a tablet/capsule;
  - colour of liquid or semi-solid dosage forms (e.g. syrup, suspension, linctus, cream, ointment);
  - colour and shape of suppositories/pessaries, etc.;
  - shape and appearance of the container.

l) Detailed and complete qualitative and quantitative composition of the finished product issued by the manufacturer. Batch formula is not accepted as alternative to the requirement. Non-proprietary names of ingredients, colour index number or E-number for all colourants used (including capsule shells) should be provided;
   (Note: Please see Remarks* below)

m) Specifications of the product issued by the manufacturer. Document(s) showing compliance with one or more of the following pharmacopoeias must be provided unless otherwise justified: Pharmacopoeia of the People’s Republic of China, British Pharmacopoeia, European Pharmacopoeia, International Pharmacopoeia, Japanese Pharmacopoeia and/or United States Pharmacopoeia. Please also refer to paragraph 9 for ‘products containing vitamins, minerals, etc.’;
   (Note: Please see Remarks* below)

Remarks*: Please refer to the “General Requirements for Master Formula and Specifications for Non-Biological Products” at Appendix 1

n) Detailed method of analysis of the product for all tests stated in the finished product specifications. Please also refer to paragraph 9 for ‘products containing vitamins, minerals, etc.’;

o) Certificate of analysis of a representative batch of the finished product,
issued by the manufacturer or the company performing the analysis;

p) Stability test data of the product at one of the following temperature
(°C)/relative humidity (RH) conditions:

Real Time Testing Condition
(i) 30°C+/-2°C/75%+/-5% RH
(ii) 30°C+/-2°C/65%+/-5% RH
(iii) 25°C+/-2°C/60%+/-5% RH

Accelerated Testing Condition
(iv) 40°C+/-2°C/75%+/-5% RH for 6 months *

*At least 3 months' real-time stability test data must be available at the
time of submission of applications on or after 1 April 2011.

Other temperature/relative humidity conditions could be adopted
where justified. Appropriate labelling of the storage conditions in English
and/or Chinese shall be provided on the sales pack.

q) Bioequivalence (BE) data:

for anti-epileptic drugs*
(* includes: Carbamazepine, Clobazam, Clonazepam, Clorazepate,
Divalproex, Ethosuximide, Ethotoin, Felbamate, Fosphenytoin,
Gabapentin, Lamotrigine, Lacosamide, Levetiracetam, Mephenytoin,
Mesuximide, Oxcarbazepine, Phenoxyuride, Phensuximide Phenyoit,
Pregabalin, Primidone, Rufinamide, Sulthim, Tiagabine, Topiramate,
Trimethadione, Vigabatrin, Valproates and Zonisamide)

for critical dose drugs / narrow therapeutic range drugs**
(with effect from 1 Aug 2016).
(** includes: Acetohexamide, Aminophylline, Aprindine,
Chloramphenicol, Choline theophylline, Clindamycin, Clonidine,
Cyclosporine, Digitoxin, Digoxin, Diprophylline, Disopyramide, Ethinyl Estradiol, Flecainide, Glibenclamide, Glitazide, Glybuzole, Glycylpyramide, Guanethidine, Isoetharine, Isoprenaline, Levodopa and Carbidopa, Levothyroxine, Lithium, Metaproterenol, Methotrexate, Minoxidil, Phenobarbital, Prazosin, Procainamide, Proxyphylline, Quinidine, Sirolimus, Tacrolimus, Theophylline, Tolazamide, Tolbutamide and Warfarin)

The BE studies should be conducted in accordance with World Health Organization guidance document: “Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability”, or other international guidelines.

(D) Soft copies of the above supporting documents must be submitted via the PRS 2.0 system in Portable Document Format (PDF) format. The original or certified true copies of the above supporting documents should be submitted to the following address:

Drug Registration and Import/Export Control Division
Drug Office, Department of Health
3/F, Public Health Laboratory Centre,
382 Nam Cheong Street,
Shek Kip Mei, Kowloon,
Hong Kong. (Enquiries: 2319 8458)

Registration of products containing vitamins, minerals, etc.

9. Special exemptions are provided for the quality analysis of products containing vitamins, minerals, etc. Please refer to the attached “Guidelines on the Testing of Pharmaceutical Products containing Vitamins, Minerals, etc.” at Appendix 3 for details.

Use of materials of animal origin

10. If materials of animal origin are used in the manufacturing of the product, you should also provide documentary evidence obtained from the manufacturer on the source of the animals, the nature of the animal tissues used in the manufacturing and the production processes, showing compliance with one or more of the safety measures taken to minimize the risk of communicable diseases that can be transmitted
to human, including but not limited to Transmissible Spongiform Encephalopathy (TSE) transmission promulgated by the European Medicines Agency, USA or Australia. The following documents are relevant:

(A) “Notes for guidance on minimizing the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products” released by the European Medicines Agency (EMEA/410/01);

(B) the general monograph of the European Pharmacopoeia on “Products with risk of transmitting agents of animal spongiform encephalopathies”;

(C) “Risk and regulatory assessment of lactose and other products prepared using calf rennet” released by the European Medicines Agency;

(D) “Guidance for Industry – the sourcing and processing of gelatin to reduce the potential risk posed by Bovine Spongiform Encephalopathy (BSE) in FDA-regulated products for human use” released by the FDA;

(E) “Supplementary requirements for therapeutic goods for minimising the risk of transmitting transmissible spongiform encephalopathies (TSEs)” released by the Therapeutic Goods Administration of Australia.

General Requirements

11. Please ensure that all the information set out in the above paragraph 8 (C) above have been provided.

12. For products of the same description, composition and strength but different package sizes, only one application is required. For instance, only one application is required for “ABC Tablet 100mg” of package sizes 10’s, 100’s and 1,000’s. However, two separate applications are required for “ABC Tablet 100mg” and “ABC Tablet 50mg”. Similarly, separate applications are required for a product presented in different dose forms, e.g. injection, tablet and capsule. One single presentation is allowed for each pack size and you should submit two separate applications for registration if you intend to market the product in two different presentations for the same pack size.

(Feb 2017)
Registration fee

13. When an application is approved, you will be required to pay a registration fee, currently at $1,370 per product. You will receive the Certificate of Drug/Product Registration when we have received the payment. Please pay by post, or via the PRS 2.0 system with credit card / PPS online payment services, or in person at the address specified in paragraph 8 above. Cheques should be made payable to “The Government of the Hong Kong Special Administrative Region” and crossed.

Hours of payment:

Monday to Friday
9:00 am – 1:00 pm
2:00 pm – 5:30 pm (Tuesday to Friday) or 5:45 pm (Monday)

Infringement of patent right

14. Please note that the Pharmacy and Poisons Board does not take the factor of “patent right” into consideration while deciding on an application for registration of a pharmaceutical product/substance. Nevertheless, an applicant shall not overlook the issue of infringement of patent right as doing the following acts in Hong Kong without the consent of the patent proprietor may be liable for infringement of a patent registered in Hong Kong:

(A) making, putting on the market, using or importing a patented product; or

(B) stocking the patented product whether for the purpose of putting it on the market (in Hong Kong or elsewhere) or otherwise.

You are therefore reminded to ensure that your product does not infringe any patent right. Please see sections 73 to 75 of the Patents Ordinance (Cap. 514) for further details. You should always consult your own lawyer if you have any doubts about your position in this regard.

Enquiries on progress of applications

(Feb 2017)
15. At any time during the application process, you can make enquiry at the Drug Registration Unit regarding the progress of the application. Please quote the file reference of the registration application when calling for enquiry.

The Guidance Notes are served as general guide to applicant of new product/substance registration and shall not be regarded as complete registration requirements or authoritative statement of the relevant laws or its interpretation on any particular case. Copies of the Pharmacy and Poisons Ordinance and its subsidiary legislations shall be referred, which can be purchased by calling the Publications Sales Section of Information Services Department at Tel: 2537 1910, or by email at puborder@isd.gov.hk. Contents of the relevant legislation can also be found at the Department of Justice’s website https://www.elegislation.gov.hk/.